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Edited by Takashi GojoboriAbstract Estimates of the number of human genes that produce
more than one transcript isoform through alternative mRNA
splicing depend on the assumption that the observation of
multiple transcripts from a gene can be attributed entirely to
alternative splicing. It is possible, however, that a substantial
proportion of cases where multiple transcripts have been
observed for a gene result from diﬀerences between alleles.
Many examples of genes that are spliced diﬀerently from
diﬀerent alleles have been reported but no systematic estimate of
the proportion of alternatively spliced genes that are aﬀected by
such polymorphisms has been carried out. We ﬁnd that
alternative transcript isoforms are non-randomly associated with
closely linked nucleotide polymorphisms, based on an integrated
analysis of the dbSNP, dbEST and ASAP databases. From the
observed level of association between transcript isoforms and
polymorphisms, we estimate that 21% of alternatively spliced
genes are aﬀected by polymorphisms that either completely
determine which form of the transcript is observed or alter the
relative abundances of some of the alternative isoforms. We
provide a conservative lower bound of 6% on this estimate and
point out that alternative splicing cannot be conﬁrmed absolutely
unless more than one transcript is observed from the same allele.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Numerous large-scale studies of alternative splicing in hu-
mans and other organisms have been carried out using ex-
pressed sequence tags (ESTs) and cDNAs [1–6] as well as,
more recently, microarrays [7]. Estimates from these studies of
the proportion of genes that produce alternative transcript
isoforms are as high as 74% [7]. The methods that have been
used to identify alternatively spliced transcripts have so far not
distinguished between allele-speciﬁc transcript isoforms (i.e.,
diﬀerent alleles produce diﬀerent transcript isoforms) and true
alternative splicing that aﬀects transcripts from the same allele.
With some exceptions (e.g. [8]), the contribution of polymor-* Corresponding author. Fax: +27-21-650-5321.
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doi:10.1016/j.febslet.2004.10.018phism to transcript variation is frequently overlooked and
remains unqualiﬁed.
Individual mutations that aﬀect mRNA splicing have been
reported, several of which have been implicated in heritable
diseases or disease susceptibility (e.g. [9–15]). In many in-
stances, an exon is skipped due to a mutation at, or close to,
the donor splice site in the intron immediately downstream of
it. In other cases, a transcript containing a premature stop
codon mutation is degraded by the nonsense-mediated decay
pathway, resulting in the accumulation of a minor alternative
splice form in which the exon is skipped [16]. More surpris-
ingly, there are several reports where aberrant splicing of a
disease allele has been associated with a missense or a silent
change in an exon and not with any changes in introns (re-
viewed in [16]). Nucleotide changes that alter splicing or that
induce nonsense-mediated mRNA decay may frequently have
a radical eﬀect on the encoded protein [17] and play an im-
portant and often neglected part in genetic variation and in
disease [18,19].
We used ESTs that can be mapped both to single nucleotide
polymorphisms (SNPs) and to exon junctions to estimate the
fraction of allele speciﬁc transcript isoforms among genes re-
ported in the ASAP database [20] to be alternatively spliced. It
is likely that many nucleotide polymorphisms that alter splic-
ing are in introns. The SNPs that we can map to EST se-
quences are exonic and in many cases may not be the cause of
the allele-speciﬁcity of transcript isoforms, but instead are in
tight linkage disequilibrium with the causal polymorphism.
Our hypothesis is that some detected exonic SNPs might be
associated with particular transcript isoforms because they are
tightly linked to other unseen intronic polymorphisms that
cause isoform allele-speciﬁcity. For simplicity, our analysis
assumes that two separate mutations, one that caused isoform
allele-speciﬁcity and one that gave rise to a nearby detectable
exonic SNP, occurred at diﬀerent times in an unknown order.
However, our approach is valid even if the observed exonic
SNP is the cause of the allele-speciﬁcity.
We consider the situation in which two mutations have oc-
curred sequentially, giving rise to two linked polymorphisms,
then (in the absence of recombination in the intervening se-
quence) the more recent polymorphism will always be found in
association with a single form of the earlier polymorphism
(Fig. 1). If one polymorphism determines completely the
transcript isoform observed and the other is detectable as an
exonic SNP, this means that one combination of transcript
isoform and SNP should never be present in EST databases.blished by Elsevier B.V. All rights reserved.
Fig. 1. Sequential mutations model. (A) A possible example of isoform
allele-speciﬁcity aﬀecting the RNPC4 gene. ESTs consistent with the
most common (longer) transcript isoform are shown on the left above
the genomic sequence and ESTs consistent with the minor isoform are
shown on the right. There are 10 ESTs that exclude exon 6, all of which
have a G at a SNP site in exon 1. Of the ESTs from transcripts that
include exon 6, ﬁve have a G at the polymorphic site and 26 have T at
this site. (B) Data matrix corresponding to the RNPC4 example (see
Section 2). (C–E) Three scenarios through which sequential mutations
could have given rise to the SNP and to the alternative isoforms of the
gene. In (C), the SNP is more ancient and was followed by a mutation
that altered mRNA splicing. The mutation that altered splicing oc-
curred on an allele bearing a G at the SNP position and resulted in the
skipping of exon 6 (red) in transcripts. In (D), a mutation occurred
that altered splicing prior to the SNP mutation. The SNP mutation
occurred on an allele that included exon 6 and consisted of a substi-
tution from G to T. (E) A stop-codon polymorphism in a cassette exon
(blue) of a generic alternatively spliced gene. The stop codon poly-
morphism is linked to an exonic SNP elsewhere on the gene, resulting
in nonsense-mediated decay of the longer isoform from the allele
containing the stop codon.
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script isoform that is observed, the choice of transcript isoform
should be independent of the SNP allele and all four isoform/
SNP combinations could occur in ESTs. We count the ESTs
manifesting each isoform/SNP combination in a 2 2 data
matrix where the columns correspond to transcript isoforms
and the rows correspond to SNP alleles (Fig. 1B).
Two types of allele-speciﬁc transcripts were considered,
which we refer to as completely and partially allele-speciﬁc. In
the case of complete allele speciﬁcity, one allele always gives
rise to the major form of the transcript and another allele al-
ways gives rise to the minor form. Alternatively, if the tran-
script isoform is partially allele-speciﬁc, then each allele may
give rise to both the major and the minor form of the transcript
but with a probability that is allele-dependent. Partial allele
speciﬁcity therefore involves changes in the frequency of
competing transcript isoforms.2. Data and methods
Genomic locations of ESTs and SNPs were downloaded from the
UCSC Genome Browser database [21] on 24/03/04. ESTs and SNPs
that mapped onto more than one genomic position were discarded. We
used these genomic coordinates to calculate the positions of SNPs
from release 120 of dbSNP on ESTs and retrieved the nucleotide at
each SNP position from the EST sequences from release 140 of dbEST.
The ASAP database of alternatively spliced genes [20] was downloaded
on 02/04/04. The data included short sequence fragments from exon
junctions associated with Unigene clusters. We mapped splice junc-
tions involved in alternative splicing to EST sequences from the same
Unigene cluster by scanning the ESTs for exact matches to the splice
junctions.
2.1. Data matrices
We considered only the two most common alleles at each SNP po-
sition and pairs of splice junctions that are associated with diﬀerent
splice isoforms from the ASAP database. This resulted in 2 2 ma-
trices of splice junctions and SNP alleles. In order to eliminate po-
tential bias resulting from multiple ESTs derived from the same tissue
sample, we restricted the matrices to a single EST per clone library per
SNP allele. Because multiple splice junctions and SNPs from the same
gene may not be independent, we considered only one SNP and one
splice junction pair per Unigene cluster for the estimates of the prev-
alence of allele-speciﬁc isoforms. In each case, the rarest splice junction
and a highly represented SNP were selected to maximize the chance of
picking up polymorphic splice isoforms that are at low frequency. The
restriction to a single SNP and splice junction per gene was not nec-
essary for the detection of individual candidates for allele-speciﬁc
splicing from statistical associations, but the restriction to just one EST
per allele per library was maintained. The matrices as well as the
mappings of SNPs and splice junctions from which they were gener-
ated are available on our website (http://www.sanbi.ac.za/snp2estmap/
febs/).
2.2. Simulations
Randomized replicates of the dataset were constructed under the
constraint that row and column sums for each matrix were conserved
and with no association between transcript isoform and the nucleotide
at the polymorphic site. The number of matrices in the replicate da-
tasets with a zero cell was counted in order to estimate the expected
number of matrices with a zero cell in the absence of an association
between transcript isoform and SNP. Conﬁdence intervals were de-
termined that included the values obtained from 95% of the replicates.
Given the number of zeros in the random datasets, we could estimate
the number of additional zeros that result from non-random rela-
tionships between the rows and columns of the matrices. In the case of
completely allele-speciﬁc isoforms, every matrix aﬀected necessarily
has at least one zero cell (Fig. 1). We also constructed randomized
datasets with a bias such that a strong, but not exclusive, association
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domly selected proportion of the matrices and estimated the propor-
tion of aﬀected matrices required to reproduce the observed number of
matrices with a zero cell.
Fisher’s Exact Test and Bonferroni correction were used to test for
statistical associations between SNPs and isoforms from individual
genes. We restricted the matrices tested to only those that could
achieve a maximal P-value of 0.001 based on their row and column
totals to reduce the correction for multiple testing.3. Results
We obtained 1295 matrices corresponding to ESTs that we
mapped to splice junctions and SNPs as described in Section 2.
Of these, 139 contained rows and columns that each summed
to at least two and were thus informative using our approach
based on counting the number of matrices with a zero cell
(matrices with a row or column that sums to one necessarily
having a zero cell). Restricting the analysis to these matrices
also ensured that only transcript isoforms represented in at
least two diﬀerent cDNA libraries or from two diﬀerent alleles
within a single library were considered. Between 4 and 137,
diﬀerent cDNA libraries were represented in each of these
matrices. Because we restricted the analysis to a single matrix
per Unigene cluster, these matrices correspond to 139 diﬀerent
Unigene clusters. In the observed data, 85 matrices had a zero
cell and were thus consistent with allele-speciﬁcity. In equiva-
lent sets of randomized matrices, on an average 71 matrices
had a zero element (Fig. 2). Only four out of 1000 replicates
had as many or more matrices with a zero cell as found in the
observed data. The observed number of matrices with at least
one zero cell (indicated by the arrow in Fig. 2) is not likely to
have resulted from random data with no relationship between
SNP allele and transcript isoforms and instead indicates the
presence of allele-speciﬁc isoforms in the data. The 14 addi-
tional matrices with a zero cell in the observed data correspond
to 21% of the average number of matrices without a zero cell in
the randomized datasets.Fig. 2. The number of matrices consistent with completely allele-speciﬁc splic
with a zero cell from 1000 randomized replicates of the dataset. The arrow iIf we consider complete allele-speciﬁcity as the only alter-
native to random association (i.e., partial allele-speciﬁcity is
not permitted), then a minimum 6% of the isoforms in the
dataset are completely allele-speciﬁc (the proportion most
consistent with the data is 21% and the maximum proportion
possible is 36%; Fig. 3A). Partial allele-speciﬁcity, where dif-
ferent alleles have diﬀerent but incomplete isoform biases, can
also increase the number of matrices with a zero cell in the data
but it does so less eﬃciently. We modeled the situation where a
proportion of the matrices in the dataset showed a strong, but
not exclusive, association between transcript isoform and nu-
cleotide polymorphism and used simulation to estimate the
expected number of matrices with a zero cell. The association
between rows and columns for the aﬀected matrices was such
that, for an individual EST, the probability of it being isoform
k given that it is SNP allele i was four times the probability of
being isoform k given that it is SNP allele j. With this fourfold
association, at least 14% of the isoforms in the dataset would
need to be partially allele-speciﬁc in order to explain the ob-
served number of matrices with a zero cell. The real data are
likely to contain a mixture of completely and partially allele-
speciﬁc isoforms. Combinations of proportions of completely
and partially allele-speciﬁc forms that would be most likely to
result in the number of zeros in the observed data are shown in
Fig. 3B.
We tested individual data matrices for non-random associ-
ations between isoforms and SNPs. An example is shown in
Fig. 1 for the gene RNPC4. The P-value for the association
between the rows and columns of the matrix shown is 0.0002
(from a 2-tailed Fishers Exact Test). The highest statistical
signiﬁcance ðP < 2 108Þ of any matrix in the dataset was
achieved for the association between this same isoform and
another SNP that was located closer to the alternatively
spliced exon junction. This association remains highly signiﬁ-
cant after correction for multiple testing, suggesting that this
gene-does indeed have polymorphic splice variants that are
found at suﬃciently high frequency in the population to being in randomized data. Histogram showing the proportion of matrices
ndicates the number of matrices with a zero cell in the observed data.
Fig. 3. Simulations of complete and partial allele-speciﬁc transcript isoforms. (A) Average numbers of matrices with a zero cell from 1000 simulated
replicates of the dataset in which a proportion of the simulated matrices are derived from completely allele-speciﬁc transcript isoforms. The hori-
zontal line shows the number of matrices with a zero cell in the observed data. The shaded area shows the conﬁdence interval and the dark line the
proportion of completely allele-speciﬁc isoforms most consistent with the observed number of matrices with a zero cell. Error bars were derived from
the simulation as described in Section 2. (B) Combinations of completely and partially allele-speciﬁc transcript isoforms that could explain the
observed number of matrices with a zero cell in the data. The points on the graph show the proportions of completely (y-axis) and partially (x-axis)
allele-speciﬁc isoforms in the simulations that result in approximately the same number of matrices with a zero as we have observed in the data. In
this example the strength of the association between rows and columns of the simulated matrices was such that, for an individual EST, the probability
of its being in column k given that it was in row i was a factor of four higher than the probability of its being in column k given that it was in row j.
236 V. Nembaware et al. / FEBS Letters 577 (2004) 233–238detectable using this method. Data matrices from 32 genes for
which we have been able to detect associations between SNPs
and splice junctions can be accessed at our website (http://
www.sanbi.ac.za/snp2estmap/febs/). However, while all data
matrices corresponding to completely allele-speciﬁc transcript
isoforms are expected to have a zero cell (in the absence of
recombination between the exon junctions and the SNP posi-
tion), statistical associations between the matrix rows and
columns occur only under speciﬁc conditions for realistic
amounts of data (e.g., the second mutation occurs on a rare
allele of the earlier polymorphism). For most individual ma-trices, there are insuﬃcient data to establish allele-speciﬁcity
with any conﬁdence, especially when correction for multiple
testing is applied.4. Discussion
The factors that control alternative splicing in mammalian
genes are imperfectly understood. Most previous studies have
concentrated on variation in splicing pattern across tissues,
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acting factors [22]. Our results indicate that cis-acting allelic
variation also plays a role in determining which splice vari-
ant is observed. However, the use of public transcript data to
estimate either the tissue-speciﬁcity [22] or the allele-speci-
ﬁcity (as studied here) of transcript isoforms is complicated
by the fact that multiple overlapping ESTs from the same
individual are present in dbEST. If there is a signiﬁcant
proportion of allele-speciﬁc transcript isoforms in human
populations, then any conservative test for tissue speciﬁcity
of isoforms should be restricted to a single EST per allele
from any one library to get a random sample of alleles.
Alternatively, if the predominant variation among transcript
isoforms is between tissues within a single individual, then
any test for allele-speciﬁcity of isoforms should be restricted
to a single EST per allele per library. In order to provide a
conservative estimate of the contribution of allele-speciﬁc
isoforms to transcript variation, we have restricted our
analysis to one sample per allele per clone library and also to
one data matrix per gene.
We propose that the allele-speciﬁcity that we report is likely
to result from nucleotide polymorphisms that aﬀect either the
meaning or the strength of splice signals or enhancers. Ex-
amples of mutations in splice signal regions that aﬀect mRNA
splicing have previously been reported [9]. It is possible,
however, that other causes contribute to the observed isoform
allele-speciﬁcity. For instance, allele-speciﬁcity could also re-
sult from a polymorphism that determines whether nonsense-
mediated decay of one isoform occurs. If the longer form of a
transcript contains a nucleotide polymorphism that results in a
stop codon in the translated product and if this polymorphic
site is absent from the shorter form, then the longer form of the
transcript would be subject to nonsense-mediated decay only
in the case of the allele containing the stop codon (Fig. 1E).
This could result in under-representation of the longer isoform
derived from the allele containing the stop codon. In this case,
both of the transcript isoforms are produced from each allele
(true alternative splicing) but the likelihood of observing both
isoforms would be reduced for the allele with the stop codon.
While we feel that this mechanism could, in theory, contribute
to allele-speciﬁcity, we are not aware that any examples of
isoform allele-speciﬁcity by this mechanism have been re-
ported. It is also possible that an apparent alternatively spliced
isoform could result directly from a polymorphic deletion
spanning an entire exon. An example of such a variant was
reported for the human growth hormone receptor [23].
Allele-speciﬁcity of transcript isoforms may be complete or
partial. A nucleotide polymorphism may alter splicing of all
transcripts of the gene so that each allele produces just one
form of the transcript (complete allele-speciﬁcity). Alterna-
tively, more than one transcript isoform may be generated
from a single allele (true alternative splicing) but the frequency
at which each isoform is found may vary between alleles
(partial allele-speciﬁcity). An example of the latter type of
polymorphism was reported in the human XPC DNA repair
gene [15], whereas in the GNB3 gene there is almost complete
association between the shorter splice variant and the 825T
allele [24,25]. Complete and partial allele-speciﬁcity can both
result in an association between transcript isoform and nu-
cleotide polymorphisms but the former will cause the strongest
association. As a consequence, our estimate of the proportion
of completely allele-speciﬁc transcript isoforms required toexplain the number of observed matrices with a zero cell
should be considered as a lower bound on the proportion of
the dataset that is aﬀected by either complete or partial allele-
speciﬁcity.
Recombination events, which should be rare when the dis-
tance between the splice junction and the SNP being moni-
tored is small compared to typical human haplotype block
sizes, can reduce the signal in the data and could cause un-
derestimation of the level of isoform allele-speciﬁcity but
cannot introduce false positive results. It is possible that
transcript isoform choice is also aﬀected by an individual’s
genotype at other unlinked loci, but dbEST-based methods are
unable to detect this. Similarly, although EST sequences are
known to be error-prone, random sequencing errors cannot
introduce false positive associations.
There are multiple potentially independent alternatively
spliced junctions for many of the genes represented in the
ASAP database. Because our estimate of the prevalence of
allele-speciﬁc isoforms took account of just one alternative
isoform per gene, the total proportion of genes from the al-
ternative splicing databases for which at least one allele-spe-
ciﬁc isoform exists may be far higher than the lower bound
presented here.
The existence of polymorphic transcript isoforms within
populations is consistent with the recent discovery that exons
found only in minor splice forms are often completely absent
from the orthologous gene in human/rodent comparisons [26–
28], because evolutionary changes in gene structure must
originate as polymorphisms within species. We provide a lower
bound of 6% for the proportion of alternatively spliced genes
for which either completely allele-speciﬁc or partially allele-
speciﬁc transcript isoforms are present in the dataset. This
lower bound was calculated based only on exon junctions from
transcript isoforms that are present in at least two diﬀerent
EST libraries and excludes the contribution to transcript di-
versity from rare mutations. Interestingly, no natural upper
bound on the proportion of alternatively spliced genes that are
aﬀected by polymorphism emerges from our analysis and we
argue that the contribution of allele-speciﬁc transcript iso-
forms should be stated as a caveat in future estimates of the
prevalence of alternative splicing. Our results emphasize that
true alternative splicing cannot be conﬁrmed unless more than
one transcript is observed from the same allele and also cau-
tion that any inference of tissue-speciﬁc splicing must take
account of allele-speciﬁcity.
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